Drug company BeiGene (SHA:688235) narrowed its first-quarter loss attributable to shareholders to 94.5 million yuan from 1.91 billion yuan the previous year.
Loss per share moderated to 0.07 yuan from 1.41 yuan, according to a Thursday filing with the Shanghai bourse.
Total operating income rose 50% year over year to 8.05 billion yuan from 5.36 billion yuan.